SG11201507618YA - Recombinant factor viii formulations - Google Patents

Recombinant factor viii formulations

Info

Publication number
SG11201507618YA
SG11201507618YA SG11201507618YA SG11201507618YA SG11201507618YA SG 11201507618Y A SG11201507618Y A SG 11201507618YA SG 11201507618Y A SG11201507618Y A SG 11201507618YA SG 11201507618Y A SG11201507618Y A SG 11201507618YA SG 11201507618Y A SG11201507618Y A SG 11201507618YA
Authority
SG
Singapore
Prior art keywords
factor viii
recombinant factor
viii formulations
formulations
recombinant
Prior art date
Application number
SG11201507618YA
Other languages
English (en)
Inventor
De Qian Wang
Xinghang Ma
Nelly Tsvetkova
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of SG11201507618YA publication Critical patent/SG11201507618YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201507618YA 2013-03-15 2014-03-11 Recombinant factor viii formulations SG11201507618YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799495P 2013-03-15 2013-03-15
US201361869191P 2013-08-23 2013-08-23
PCT/US2014/023357 WO2014150477A1 (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations

Publications (1)

Publication Number Publication Date
SG11201507618YA true SG11201507618YA (en) 2015-10-29

Family

ID=51580768

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201507618YA SG11201507618YA (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations
SG10201803999UA SG10201803999UA (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201803999UA SG10201803999UA (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations

Country Status (17)

Country Link
US (1) US20160030524A1 (https=)
EP (1) EP2970430A4 (https=)
JP (1) JP2016518321A (https=)
KR (1) KR20150132449A (https=)
CN (1) CN105209487A (https=)
AU (1) AU2014237111B2 (https=)
BR (1) BR112015022730A2 (https=)
CA (1) CA2905739A1 (https=)
HK (1) HK1213273A1 (https=)
MX (1) MX2015012905A (https=)
PE (1) PE20160121A1 (https=)
RU (1) RU2015144076A (https=)
SG (2) SG11201507618YA (https=)
TW (1) TW201521761A (https=)
UY (1) UY35412A (https=)
WO (1) WO2014150477A1 (https=)
ZA (1) ZA201507684B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190064147A1 (en) * 2015-01-18 2019-02-28 Biogen Ma Inc. Formulations and screening of biological therapeutic agents
EP3374387A1 (en) 2015-11-13 2018-09-19 Baxalta Incorporated Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
EP3823985A1 (en) 2018-07-16 2021-05-26 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
EP4013389A1 (en) * 2019-08-16 2022-06-22 Octapharma AG Stabilizing buffer for factor viii and vwf

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP1152450A4 (en) * 1999-02-01 2004-04-14 Nippon Electric Glass Co CATHODE RAY TUBE AND METHOD FOR THE PRODUCTION THEREOF
EP2921180B1 (en) * 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
US7205278B2 (en) * 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
KR101468345B1 (ko) * 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Fviii의 부위 지향 변형
CA2647314A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
NZ593190A (en) * 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
WO2010083536A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety

Also Published As

Publication number Publication date
HK1213273A1 (zh) 2016-06-30
JP2016518321A (ja) 2016-06-23
EP2970430A1 (en) 2016-01-20
BR112015022730A2 (pt) 2017-10-31
CN105209487A (zh) 2015-12-30
PE20160121A1 (es) 2016-03-03
MX2015012905A (es) 2016-06-16
RU2015144076A (ru) 2017-04-24
ZA201507684B (en) 2017-06-28
SG10201803999UA (en) 2018-06-28
WO2014150477A1 (en) 2014-09-25
KR20150132449A (ko) 2015-11-25
UY35412A (es) 2014-10-31
AU2014237111A1 (en) 2015-10-08
EP2970430A4 (en) 2017-01-11
US20160030524A1 (en) 2016-02-04
AU2014237111B2 (en) 2018-06-21
CA2905739A1 (en) 2014-09-25
TW201521761A (zh) 2015-06-16

Similar Documents

Publication Publication Date Title
SG11201505924TA (en) Factor viii polypeptide formulations
GB201319791D0 (en) Formulations
GB201319792D0 (en) Formulations
SG11201505926VA (en) Factor ix polypeptide formulations
IL245420A0 (en) New formulations
ZA201600729B (en) Peptides
GB201304973D0 (en) Recombinant protein
ZA201507684B (en) Recombinant factor viii formulations
ZA201504986B (en) Peptide
HUE050164T2 (hu) Új négy-CTL epitóp-kapcsolt peptid
ZA201504987B (en) Peptide
PL2983690T3 (pl) Peptydy pochodzące od neuropeptydu Y
GB201315130D0 (en) Peptides
IL244956B (en) New peptide compositions
GB201308860D0 (en) Delivery peptides
GB201316660D0 (en) Peptides
GB201300381D0 (en) Peptides
GB201305465D0 (en) Novel peptides
GB201300529D0 (en) Recombinant polypeptide